pevonedistat

Takeda gets FDA breakthrough therapy status for pevonedistat to treat higher-risk HR-MDS
Pharmaceutical Business Review
Fri, 07/31/20 - 10:42 am
Takeda Pharmaceuticals
breakthrough status
FDA
pevonedistat
myelodysplastic syndrome